To Assess the Pharmacokinetics and Safety and Tolerability of Efanesoctocog Alfa (BIVV001)in Adults With Type 2N and 3 Von Willebrand Disease (VWD)

Duration of each part of the study for one participant:

Total study duration: Up to 57 days.

* Screening: up to 28 days.
* Up to 29 days of safety observation following the IV BIVV001 dose administration (this period includes PK sampling up to the first 10 days following administration).

• efanesoctocog alfa (BIVV001) (Drug): Pharmaceutical form:solution for injection Route of administration: intravenous injection

Primary outcomes

• Pharmacokinetic Parameter: Maximum plasma concentration observed (Cmax) [Day 1 to Day 10]
• Pharmacokinetic Parameter: Terminal half-life (t½z) [Day 1 to Day 10]
• Pharmacokinetic Parameter: Total Clearance (CL) [Day 1 to Day 10]
• Pharmacokinetic Parameter: Volume of distribution at steady state (Vss) [Day 1 to Day 10]
• Pharmacokinetic Parameter: Area under the activity time curve extrapolated to infinity (AUC∞) [Day 1 to Day 10]
• Pharmacokinetic Parameter: Mean residence time (MRT) [Day 1 to Day 10]
• Pharmacokinetic Parameter: Incremental recovery (IR) [Day 1 to Day 10]

Secondary outcomes

• Number of participants with adverse events [Up to Day 29]

Sex: All, ages: 18 Years to 65 Years

Inclusion criteria :

\-- Male and/or female participant, between 18 and 65 years of age, inclusive at the time of informed consent.

* The participant has been diagnosed with hereditary type 3 VWD or type 2N VWD as documented in historical medical records OR a documented genotype known to produce VWD type 3 or 2N VWD.
* Type 3 VWD participants are included if they have a medical history of at least 25 exposure days to VWF and factor VIII-containing coagulation factor concentrates
* Type 2N VWD participants are included if the use of DDAVP is deemed insufficient or contraindicated, as assessed by the Investigator, or if they have required prior use of VWF- and FVIII- containing coagulation factor concentrates.

Exclusion criteria:

* Hereditary or acquired coagulation disorder other than VWD (including qualitative and quantitative platelet disorders, and thrombocytopenia < 100,000 cells/uL at Screening)
* The participant has a FVIII activity levels >20 IU/dL, at Screening
* History or presence of a VWF inhibitor or clinical suspicion of a VWF inhibitor
* History of a positive FVIII inhibitor test, defined as ≥0.6 BU/mL (by Nijmegen modified Bethesda assay) or a clinical suspicion of a FVIII inhibitor
* Positive FVIII inhibitor test, defined as ≥0.6 BU/mL, at Screening
* History of hypersensitivity or anaphylaxis associated with any FVIII- or VWF- containing product
* The participant has received or anticipates receiving systemic immunosuppressive or immunomodulatory treatment within 12 weeks prior to Baseline.
* The participant requires the use of acetylsalicylic acid, non-NSAID anti-platelets, and NSAIDs above the maximum dose product
* Patients currently on a prophylaxis regimen for the treatment of VWD that, in the Investigator's opinion, would preclude participation in the study due to the possible increased risk of bleeding associated with the requirement to withhold prophylaxis during the study.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

• Clinical Sciences & Operations, Study director, Sanofi